Eikon Therapeutics
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Eikon Therapeutics
- Company name
- Eikon Therapeutics
- Organisation type
- Industry
- Registered legal name
- Eikon Therapeutics, Inc.
- US industry code (SIC)
- Biological products, (no disgnostic substances)
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001861123
Related records
Trials (11)
- A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
- A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
- Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors
- BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
- BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
- BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
- Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.